So this Investor should still feel comfortable investing in a company that claimed to have met all endpoints in AD and has not retracted that statement leaving them open to class action?
The old cry "if Johnny did it his mom wouldn't punish him!!" Not only would Johnny get punished, Johnny wasn't the one who stole candy. Delusion and denial. What a combo.
Biogen's Lecanemab TLR was well done and typical for biotechs and pharmas. The results themselves are positive but far from great, esp given the treatment cost and SAE's.
News 
Market Data 
Discover 
AI
